Covid-19 roundup: EMA starts rolling re­view of As­traZeneca vac­cine; No­vavax ex­ecs sell mil­lions in stock ahead of PhI­II

Though stud­ies for the Covid-19 vac­cine be­ing de­vel­oped by As­traZeneca and Ox­ford Uni­ver­si­ty re­searchers re­main on hold in the US, Eu­rope is speed­ing up its re­view.

The EMA an­nounced Thurs­day that it is ini­ti­at­ing the first rolling re­view of the vac­cine can­di­date, a move that would ac­cel­er­ate the fu­ture ap­proval process. By do­ing so, the agency’s hu­man med­i­cines com­mit­tee has start­ed eval­u­at­ing the first batch of da­ta, though it not­ed that much of the ev­i­dence has yet to be sub­mit­ted.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER